Cancer Moonshot Round 2 Focuses On Screening; Pharma To Participate In New Summit
Executive Summary
The initial moonshot aimed to increase cancer research while the reboot seeks to boost screenings to reduce death rate. New cancer cabinet mirrors previous task force. Biopharmaceutical companies are to participate in summit to highlight new commitments.
You may also be interested in...
ARPA-H: New Health Research Agency Faces Old Concerns About Disrupting Private Investment
Proposed Advanced Research Project Agency for Health also needs to distinguish itself from NCATS, which faced many of the same questions when it was created a decade ago. Disagreements also persist about whether ARPA-H should be housed in NIH or HHS.
Biden’s ‘Advanced Research’ Agency May Have Pros And Cons, Congressional Research Service Concludes
CRS poses series of questions about how a new federal agency tasked with speeding translational research for treating high-impact diseases would work, including potential downsides and whether it would duplicate government programs already in place.
Cancer 'Moonshot' Recommendations On R&D Have Strong Patient Focus
Blue ribbon panel has plenty of industry-friendly recommendations on ways to accelerate oncology science, but with the clock ticking down on the Obama Administration, the question is whether the recommendations have any political traction.